🇺🇸 FDA
Pipeline program

First-in-Human Study of ALN-SNCA in Adult Participants with Early Parkinson’s Disease (PD)

ALN-SNCA-PD-2482

Phase 1 other active

Quick answer

First-in-Human Study of ALN-SNCA in Adult Participants with Early Parkinson’s Disease (PD) for Parkinson's disease is a Phase 1 program (other) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharma Mar S.A.
Indication
Parkinson's disease
Phase
Phase 1
Modality
other
Status
active

Clinical trials